Realizing the potential of tissue-targeted RNA therapies

miRecule™ is a biotechnology company developing RNA therapies for cancer and muscular dystrophy. Our approach to drug design revolves around using genomic patient data to create highly tailored therapeutics designed to help patients live a life free from the debilitating symptoms of their disorders.

 

Our proprietary DREAmiR™ platform utilizes genomic and outcome data from thousands of patients to identify underlying genetic changes that cause their disease, and then creates a novel RNA therapeutic that can directly target and fix that genetic abnormality.

 

miRecule is currently applying the DREAmiR™ platform to develop first-in-class therapies for neuromuscular diseases.

 

Mirecule Expands Strategic FSHD Collaboration with Sanofi

GAITHERSBURG, Md.--(BUSINESS WIRE)--Mirecule, Inc., a leader in Antibody RNA Conjugate (ARC) therapeutics targeting rare neuromuscular diseases, today announced an expansion of its strategic collaboration with Sanofi. This collaboration focuses on delivering...

miRecule Selected as Featured Company Presenter at Mid Atlantic Capital Conference

GAITHERSBURG, MD – October 28, 2025 – Anthony Saleh (CEO) will present miRecule at the upcoming MACC Conference in Philadelphia on Thursday, October 30 at 12:10 PM, as part of the Healthcare-Biotech track companies presenting at the conference.

miRecule to Present at the 21st Annual Meeting of the Oligonucleotide Therapeutics Society

GAITHERSBURG, MD – October 9, 2025 – miRecule, Inc. today announced that Dr. Hunter Wallace will present data from its collaboration with Sanofi at the 21st Annual Meeting of the Oligonucleotide Therapeutics Society (OTS) in Budapest, Hungary. The presentation will...

miRecule, Inc. Announces Issuance of New Patent Broadly Covering Lead RNA Therapeutics

GAITHERSBURG, MD – October 1, 2024 – miRecule, a biopharmaceutical company focused on developing antibody RNA conjugate-based therapeutics for rare genetic diseases and other conditions, today announced the issuance of U.S. Patent No. 12,104,157, titled "Targeted...

Mirecule Wins MedCity INVEST 2024 Competition

Chicago, May 2024 — miRecule, a cutting-edge startup focused on developing antibody RNA conjugate therapeutics, clinched the top spot at the prestigious MedCity INVEST Biopharma track competition held at the Ritz Carlton in Chicago. The event, presented by MedCity...

miRecule and Sanofi discuss the potential of RNA Therapeutics for treatment of Rare Diseases

miRecule and Sanofi have partnered to pioneer innovative approaches in rare diseases and advance a novel RNA therapeutic for patients with the genetic disorder FSHD. miRecule’s DREAmiR™ discovery platform, combined with Sanofi’s Nanobody® technology, enables the...